Compare Gilead Sciences, Inc. (GILD) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Alphabet Inc Class A — how do they compare? Gilead Sciences, Inc. trades at $148.68 (market cap $182.40B), while Alphabet Inc Class A trades at $351.99 (market cap $4.24T). The key difference: Alphabet Inc Class A is far larger — about 23.2× Gilead Sciences, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Alphabet Inc Class A for 85 Days on average.
| GILD | GOOGL | |
|---|---|---|
Market Cap | $182.40B | $4.24T |
Volume | 4,469,821 | 23,392,850 |
Sector | Health | Media |
52-Week High | $155.80 | $402.62 |
52-Week Low | $116.74 | $236.59 |
Typical Hold Time | 111 Days | 85 Days |
Enterprise Value | $205.46B | $4.13T |
Dividend Yield | 2.23% | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
GOOGL trades at $350.50, up 0.81% with strong technical momentum and bullish moving average signals. The company demonstrates exceptional financial performance with 2025 revenue of $402.84B and net income of $132.17B, achieving consistent earnings beats. Recent news highlights AI-driven growth opportunities through partnerships with Anthropic and SpaceX, while YouTube's subscription price increases signal revenue diversification. Analyst consensus remains overwhelmingly positive with 87% buy ratings.
Outlook remains favorable given strong fundamentals and AI leadership, though regulatory risks and market volatility present challenges. The $431.83 consensus price target implies 23% upside potential. Investment opportunity centers on sustained AI monetization and cloud growth, balanced against antitrust scrutiny and competitive pressures in digital advertising.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
